Compare Expedia Group Inc (EXPE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Expedia Group Inc trades at $275.05 (market cap $32.97B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Expedia Group Inc is far larger — about 4.5× Spyre Therapeutics Inc. Common Stock's market cap, and Expedia Group Inc pays a 0.7% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EXPE | SYRE | |
|---|---|---|
Market Cap | $32.97B | $7.35B |
Volume | 1,375,250 | 1,624,631 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $108.92 |
52-Week Low | $188.51 | $22.18 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $31.53B | $6.35B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $273.44, up 1.85% with strong technical momentum above key support levels. The company demonstrates robust fundamentals with consistent earnings beats, 90% gross margins, and improving cash flow generation. Recent news highlights competitive threats from AI shopping agents but also strong B2B booking growth outpacing peers. Analyst consensus remains divided with a $335 price target representing 22% upside potential.
Expedia presents a compelling growth story with solid execution but faces significant AI disruption risks. The stock offers attractive valuation multiples and strong profitability metrics, though competitive pressures from Meta's Muse AI agent and ongoing layoffs create near-term uncertainty. Institutional positioning remains mixed with recent downgrades offset by positive earnings momentum.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
